Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-04-01

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the subjective and behavioral effects of cannabis products labeled as indica, sativa, or generic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Testing the Effects of Different THC Doses on Psychological and Biological Function

NCT07346690

Evaluate PK Profile Evaluate PD Profile Healthy Adults +1 more

NOT_YET_RECRUITING PHASE1

Cannabinoids, Learning, and Memory

NCT02407808

Cannabis Psychotic Disorders

ACTIVE_NOT_RECRUITING PHASE1

Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance

NCT06351540

Cannabis Use Impaired Driving Cognitive Impairment

NOT_YET_RECRUITING PHASE1

The Effects of Cannabidiol and ∆-9-THC in Humans

NCT01180374

Healthy

COMPLETED EARLY_PHASE1

Behavioral Pharmacology of THC and D-limonene

NCT03609853

D-limonene and THC Pharmacodynamics

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical laboratory study will be double-blind, placebo-controlled and will utilize a within-subjects experimental design. Participants will complete 6 outpatient drug administration sessions that will consist of self-administration of smoked cannabis (0, or 25mg THC) labeled as indica, sativa, or generically-labelled. Primary outcomes include performance on cognitive and psychomotor assessments, subjective drug effects, and simulated driving performance. Smoking topography will also be characterized.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Intoxication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

All participants will complete all dose conditions (study arms) in a randomized order

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Intervention Type DRUG

Cannabis will be administered via smoked inhalation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis

Cannabis will be administered via smoked inhalation.

Intervention Type DRUG

0 mg THC (placebo)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have provided written informed consent.
* Be between the ages of 21 and 55
* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
* Test negative for drugs of abuse including breath alcohol at the screening visit and at clinic admission
* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. Participants must confirm use of appropriate birth control methods (e.g., condoms, birth control pills) throughout the entirety of the study.
* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
* Have prior experience smoking cannabis but not currently using more than 3 times per week on average; participants must be active cannabis users (i.e., report past 3-month use) to participate.

Exclusion Criteria

* Self-reported use of illicit drugs (e.g., amphetamine, cocaine, methamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.
* History of or current evidence of significant medical (e.g., seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
* History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
* Enrolled in another clinical trial or having received any drug as part of a research study within 30 days prior to dosing.
* Having previously sought medical attention to manage adverse effects following acute cannabis use
* Individuals with anemia or who have donated blood in the prior 30 days

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes